Brunello Cucinelli Reaffirms Growth Targets Amid Short-Seller Scrutiny

02-10-2025


Brunello Cucinelli, the Italian luxury fashion house, has reported robust financial performance for the first nine months of 2025, with revenues reaching €1.02 billion, representing growth of 10.8% at current exchange rates and 11.3% at constant rates. The company's third-quarter results were particularly strong, with sales of €335.5 million showing 12% growth at current rates and 12.4% at constant rates. These results mark the first time the company has surpassed the €1 billion revenue threshold by the end of September.

The strong performance comes amid market turbulence following allegations from Morpheus Research regarding potential sanctions violations in Russia and inventory management concerns. Cucinelli responded to these allegations by stating the company "respects the rules" regarding sanctions and maintains "a fair and balanced warehouse" consistent with historical values. The company's stock initially dropped 17 percentage points following the allegations but has since recovered, gaining 18% over the past five days and trading up approximately 2% following the earnings release.

Brunello Cucinelli, the company's chairman and creative director, expressed confidence in the brand's trajectory, confirming growth targets of "around 10%" for both the current year and 2026. The company cited "excellent start" to autumn-winter collection sales and strong performance in the Spring-Summer 2026 campaign as key drivers for maintaining these targets. Retail channel sales showed particularly strong growth at 13.9% in the third quarter, while wholesale grew by 9%.

Management emphasized the quality of sales and expressed confidence that profitability would mirror the strong revenue performance. The company noted receiving "extremely positive judgments" for its women's collection during Milan Fashion Week for style, craftsmanship, quality, and exclusivity. Despite the recent market challenges, Cucinelli stated the company is "working normally" and remains unconcerned about brand image impact, pointing to "countless testimonies of appreciation" from customers and stakeholders.

Recommended news

Simeone's Torino Future Secured as Cairo Reveals Automatic Purchase Clause

2025-10-20T12:02:16.450Z

Torino president Urbano Cairo has confirmed that striker Giovanni Simeone is effectively already a permanent signing for the club, revealing that the Argentine's loan deal includes an "easily triggered" mandatory purchase clause. Speaking on Rai Radio 1's Radio Anch'io Sport program, Cairo...

Read more


Ranucci's Report to Resume Broadcasts Despite Recent Bombing Incident Near Home

2025-10-20T12:01:56.938Z

Sigfrido Ranucci, the prominent journalist and host of the investigative program Report, has returned to television following a bombing incident on October 17th near his residence in Pomezia. During an appearance on Monica Maggioni's program "In mezz'ora," Ranucci announced the upcoming...

Read more


Structural Failure in Southern Italy Leaves Three Children Hospitalized

2025-10-20T12:01:37.554Z

A retaining wall collapse in the Fiume neighborhood of Gioia Tauro, in Italy's southern Calabria region, left three siblings injured while they were playing in a courtyard near their home. The incident involved two eight-year-old twins and their thirteen-year-old brother, who were caught by...

Read more


Mafia Infiltration in Aeolian Islands Cruise Business Uncovered in Major Asset Confiscation

2025-10-20T12:02:38.132Z

Italian financial police in Catanzaro have executed a definitive confiscation order for assets valued at over €1.6 million from an individual connected to the Accorinti crime clan of Briatico. The seizure includes a land parcel with an overlying building and ownership shares in a local...

Read more


Breakthrough ADC Therapy Shows Promise Against Aggressive Breast Cancer

2025-10-20T12:00:59.574Z

Significant advances in the treatment of triple-negative breast cancer (TNBC), one of the most aggressive forms of breast cancer, were highlighted at the European Society for Medical Oncology (ESMO) congress. New data from Phase 3 clinical trials demonstrate that antibody-drug conjugates...

Read more